Open AccessT100: Long term Follow‐up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG‐ACRIN Research Group (E4412: Arms A‐I)
Author(s) -
Diefenbach Catherine,
Jegede Opeyemi,
Ambinder Richard,
Cohen Jonathon,
Robertson Michael,
David Kevin,
Advani Ranjana,
Fenske Timothy,
Barta Stefan,
Palmisiano Neil,
Svoboda Jakub,
Morgan David,
Karmali Reem,
Kahl Brad,
Ansell Stephen M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890968.53519.f4
Subject(s) - medicine , nivolumab , rash , brentuximab vedotin , ipilimumab , gastroenterology , nausea , adverse effect , pneumonitis , surgery , lymphoma , cancer , immunotherapy , lung , hodgkin lymphoma